Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tazemetostat - Ipsen

Next Previous
Drug Profile

Tazemetostat - Ipsen

Alternative Names: E-7438; EPZ-6438; EZ-438; IPN-60200; Tazemetostat hydrobromide - Ipsen; Tazverik

Latest Information Update: 13 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Epizyme
  • Developer Eisai Co Ltd; Epizyme; Genentech; HUTCHMED; Ipsen; National Cancer Institute (USA); Pfizer
  • Class Amines; Antineoplastics; Benzamides; Biphenyl compounds; Dihydropyridines; Morpholines; Small molecules
  • Mechanism of Action Enhancer of zeste homolog 2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chordoma; Sarcoma; Follicular lymphoma; Soft tissue sarcoma; Diffuse large B cell lymphoma; Mesothelioma; Rhabdoid tumour
  • New Molecular Entity Yes

Highest Development Phases

  • Market Withdrawal Follicular lymphoma; Sarcoma
  • Discontinued Bladder cancer; CNS cancer; Diffuse large B cell lymphoma; Endometrial cancer; Histiocytosis; Lymphoma; Mantle-cell lymphoma; Mesothelioma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Ovarian cancer; Prostate cancer; Rhabdoid tumour; Solid tumours; Synovial sarcoma

Most Recent Events

  • 09 Mar 2026 Discontinued - Phase-III for Follicular lymphoma (Combination therapy, Second-line therapy or greater) in Brazil (PO)
  • 09 Mar 2026 Discontinued - Phase-III for Follicular lymphoma (Combination therapy, Second-line therapy or greater) in Turkey (PO)
  • 09 Mar 2026 Discontinued - Phase-III for Follicular lymphoma (Second-line therapy or greater, Combination therapy) in Singapore (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top